Drug manufacturer Novo Nordisk for the third time this year has announced refunds for 340B overcharges due to revisions of Medicaid pricing data.
The U.S. Health Resources and Services Administration posted the company’s notice to covered entities on its website yesterday. Novo Nordisk is issuing refunds for purchases of eight NDCs of Novoeight, a treatment and prophylactic for patients with hemophilia type A, for the period Q1-Q2 2020. The notice includes contact information for covered entities that believe they are due a refund but have not been contacted by the 340B prime vendor Apexus by Jan. 30, 2023.
Thirty-two manufacturers have posted 340B ceiling price overcharge notices on HRSA’s website this year, breaking last year’s record of 18 notices.
Novo Nordisk is one of the 18 manufacturers that imposes conditions on 340B pricing when covered entities use contract pharmacies. A federal appeals court is expected to rule on its policy’s legality early next year.
